Tevogen Bio Expanding Its Pipeline To Include Non-Oncology Products, An Approach Aimed At Maximizing ROI From Its ExacTcell Technology

Benzinga · Oct 12 00:14

Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.
Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell technology.

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to meet the high unmet needs of cancer patients. The company is pursuing a prudent commercialization strategy with a focus on its ExacTcell technology platform, which leverages precision T cell therapies to address supportive care for cancer patients.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Tevogen Bio Expanding Its Pipeline To Include Non-Oncology Products, An Approach Aimed At Maximizing ROI From Its ExacTcell Technology

Risk Disclaimer